Healthcare services company Chemed Corporation (NYSE: CHE) announced better-than-expected revenue in Q2 CY2026, with sales up 8.8% year on year to $673.3 million. Its non-GAAP profit of $6.06 per share was 8.2% above analysts’ consensus estimates.

Is now the time to buy CHE? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Chemed’s Q2 results exceeded Wall Street’s expectations, prompting a positive response from investors. Management attributed the performance primarily to strong patient volume growth and improved admission trends at VITAS, where hospital-based admissions and expansion in new Florida markets drove higher utilization. CEO Kevin McNamara highlighted that VITAS “continues to add ADC through accelerated admissions from non-preadmission locations while also maintaining a high level of hospital-based admissions.” At Roto-Rooter, commercial business manager programs contributed to revenue growth, although increased marketing spend due to a higher reliance on paid leads was a notable headwind.

Looking forward, Chemed’s full-year outlook is supported by ongoing patient census growth at VITAS, continued expansion into new counties, and disciplined cost management. Management believes that strategic balancing of referral sources and the development of new inpatient units will help sustain current margin levels. CFO Michael Witzeman indicated that back office costs are expected to grow at half the rate of revenue, enabling margin leverage. At Roto-Rooter, while management is cautious about further improvements in free lead generation, they are focused on offsetting higher marketing costs with ancillary services and franchise acquisitions.

Key Insights from Management’s Remarks

Management credited Q2 performance to strong operational execution at VITAS and targeted growth initiatives at Roto-Rooter, while acknowledging persistent challenges from rising marketing expenses and shifting referral patterns.

• VITAS admissions strategy: Management emphasized that growth in average daily census (ADC) was driven by a mix of hospital-based and non-preadmission location admissions, with new Florida markets contributing significantly. Admissions in these new counties are exceeding expectations, helping address past constraints caused by Medicare cap issues.
• Margin improvement at VITAS: The company achieved higher EBITDA margins at VITAS by balancing short-stay hospital patients with longer-stay home-based patients. Management expects this approach to sustain profitability, as hospital-based admissions remain high and labor costs are controlled.
• Roto-Rooter commercial growth: The commercial business manager program delivered above-average branch revenue growth, with branches led by these managers outperforming those without. Management sees further opportunity to expand this model to more branches for incremental gains.
• Marketing cost headwinds: Roto-Rooter faced increased marketing expenses due to a greater proportion of paid leads versus free internet leads. Management stated that free leads have steadily declined, and they are actively seeking alternative lead sources to reduce reliance on paid channels like Google.
• Franchise acquisitions and market expansion: Chemed invested in acquiring Roto-Rooter franchises in strategic locations, viewing these as long-term growth drivers. Management anticipates further acquisitions before year-end, while also monitoring opportunities to expand VITAS into new markets with high barriers to entry.

Drivers of Future Performance

Chemed’s outlook for the remainder of the year hinges on sustaining patient growth at VITAS, managing marketing expenses at Roto-Rooter, and executing on acquisition opportunities.

• Sustained VITAS growth: Management expects VITAS to maintain high-single-digit revenue growth, supported by strong hospital-based admissions and continued expansion in newly entered Florida counties. The team is confident that existing strategies and operational discipline will underpin stable long-term growth rates.
• Margin and cost management: The company aims to preserve VITAS margins by keeping back office and labor costs in check, with management reiterating their goal for SG&A growth to remain below revenue growth. At Roto-Rooter, efforts to expand ancillary services and improve collections are intended to offset persistent marketing cost pressures.
• Acquisition and regulatory environment: Chemed is focused on acquiring additional Roto-Rooter franchises and expanding VITAS into certificate-of-need (CON) states or markets with restricted entry. Management is closely monitoring regulatory developments in hospice, such as the possible end of moratoriums and changes to reimbursement, but does not expect material disruption in the near term.

Catalysts in Upcoming Quarters

In the coming quarters, our analyst team will be tracking (1) the ramp-up of patient admissions and census in VITAS’s new Florida counties, (2) stabilization or improvement in Roto-Rooter’s marketing efficiency and conversion rates for ancillary services, and (3) the pace and integration of new franchise acquisitions. Regulatory updates impacting hospice reimbursement and expansion opportunities in certificate-of-need states will also be important indicators.

Chemed currently trades at $537.10, up from $517.63 just before the earnings. At this price, is it a buy or sell? The answer lies in our full research report (it’s free).

Our Favorite Stocks Right Now

ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.

Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.